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BACKGROUND: Class III b-tubulin overexpression is a marker of resistance to microtubule disruptors in vitro, in vivo and in the clinic for
many cancers, including breast cancer. The aims of this study were to develop a new model of class III b-tubulin expression, avoiding
the toxicity associated with chronic overexpression of class III b-tubulin, and study the efficacy of a panel of clinical and pre-clinical
drugs in this model.
METHODS: MCF-7 (ERþve) and MDA-MB-231 (ER ve) were either transfected with pALTER-TUBB3 or siRNA-tubb3 and 24h later
exposed to test compounds for a further 96h for proliferation studies. RT–PCR and immunoblotting were used to monitor the
changes in class III b-tubulin mRNA and protein expression.
RESULTS: The model allowed for subtle changes in class III b-tubulin expression to be achieved, which had no direct effect on the
viability of the cells. Class III b-tubulin overexpression conferred resistance to paclitaxel and vinorelbine, whereas downregulation of
class III b-tubulin rendered cells more sensitive to these two drugs. The efficacy of the colchicine-site binding agents, 2-MeOE2,
colchicine, STX140, ENMD1198 and STX243 was unaffected by the changes in class III b-tubulin expression.
CONCLUSION: These data indicate that the effect of class III b-tubulin overexpression may depend on where the drug’s binding site is
located on the tubulin. Therefore, this study highlights for the first time the potential key role of targeting the colchicine-binding site,
to develop new treatment modalities for taxane-refractory breast cancer.
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The high percentage of non-responders and failures following
initial responses to taxanes (taxotere and paclitaxel) highlights the
critical role played by drug resistance mechanisms in breast cancer
progression. Although many mechanisms associated with resis-
tance have been proposed for taxane-refractory cells, only two
have been found in the clinic to date: the overexpression of ABC
proteins such as the P-glycoprotein (MDR1) and alterations in
tubulin-isoform expression (Correnti et al, 1995; Linn et al, 1995;
Kavallaris et al, 1997; Mozzetti et al, 2005; Paradiso et al., 2005).
Mutations within tubulin at the paclitaxel-binding site have been
identified (Giannakakou et al, 1997), which were thought to be
associated with taxane resistance. However, subsequent studies
showed that these early findings resulted from the amplification of
tubulin pseudogenes (Noguchi, 2006). Further studies have failed
to confirm the presence of tubulin point mutations in patients
with lung or ovarian cancers resistant to therapy (Sale et al, 2002;
Tsurutani et al, 2002; Lamendola et al, 2003). Microtubule-
targeting agents bind to the b-tubulin subunit of the a/b-tubulin
heterodimers that assemble to form microtubules. In humans, at
least seven distinct b-tubulin isotypes have been reported. Altered
patterns of expression are seen in cancer. In ovarian cancer
patients class III b-tubulin mRNA is significantly upregulated
in the taxane-resistant tumours compared with biopsy samples
from untreated tumours (Kavallaris et al, 1997). In a separate
study, class III b-tubulin mRNA and protein were shown to
be significantly upregulated in a sub-set of paclitaxel resistant
ovarian cancer patients (Mozzetti et al, 2005). In breast cancer
high expression of class III b-tubulin is a predictive bio-
marker of clinical paclitaxel resistance (Tommasi et al, 2007). In
gastric cancer patients, whose tumours were positive for class III
b-tubulin expression were significantly less likely to respond
to docetaxel-based chemotherapy, 16.7 vs 64.3% response rate,
respectively. Therefore, class III b-tubulin can be regarded as a
predictive marker for the clinical response to docetaxel-based
chemotherapy in gastric cancer (Urano et al, 2006). The ongoing
development of new agents, not sensitive to class III b-tubulin
overexpression, may provide new treatment options for treatment-
refractory cancer.
In this study, the effects of seven microtubule targeting
agents on the proliferation of MCF-7 and MDA-MB-231 breast
carcinoma cells over- or underexpressing class III b-tubulin were
investigated. Five of the agents, 2-methoxyoestradiol-3,17-O,
O-bis-sulfamate (STX140), 2-ethyloestradiol-3,17-O,O-bis-sulfa-
mate (STX243), 2-methoxyoestradiol (Panzem), colchicine and
ENMD1198 are known to target the colchicine-binding site on
tubulin, the other two target the taxane-binding site (paclitaxel)
and the vinca-binding site (vinorelbine). These seven agents
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vinorelbine), those drugs that are currently in/have recently
completed phase I trials (2-MeOE2 and ENMD1198) and a new
generation of orally bioavailable compounds which are in
advanced pre-clinical development (STX140 and STX243).
MATERIALS AND METHODS
Drug synthesis
2-Methoxyoestradiol (2-MeOE2, Figure 1 compound I) was synthe-
sised as described previously (Leese et al, 2005a). 2-Methoxy-
oestradiol-3,17-O,O-bis-sulfamate (STX140, Figure 1 compound II)
and 2-ethyloestradiol-3,17-O,O-bis-sulfamate (STX243, Figure 1
compound III) were synthesised by reaction of the appropriate 2-
substituted oestradiol in dimethyl acetamide solution with
sulphamoyl chloride (Leese et al, 2005b, 2006). 2-Methoxyoestra-
1,3,5(10),16-tetraene-3-carboxamide (ENMD1198, IRC110160,
Figure 1 compound VI) was synthesised as described in US2005/
203075 (Foster et al, 2008). Paclitaxel (Figure 1 compound IV,
Sigma, Poole, UK), vinorelbine (Figure 1 compound V, Sigma) and
colchicine (Figure 1 compound VII, Sigma) were purchased from
commercial sources.
Cell culture
MCF-7 (ERþve) and MDA-MB-231 (ER ve) human breast cancer
cells were obtained from the American Type Culture Collection
(LGC Promochem, Teddington, UK). Cells were cultured in RPMI
1640 medium supplemented with 10% (v/v) foetal calf serum,
1% L-glutamine (200mM), 1% non-essential amino acids (100 )
and 1% bicarbonate (7.5%) from Sigma and maintained in a
humidified incubator under 5% CO2 atmosphere at 371C.
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Figure 1 Structures. I: 2-MeOE2, II: STX140, III: STX243, IV: paclitaxel, V: vinorelbine, VI: ENMD1198 and VII: colchicine.
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The protein-expression vector (pALTER-TUBB3) was prepared by
inserting the full-length human class III b-tubulin cDNA fragment
from pOTB7-TUBB3 (LGC Promochem) into pALTER Max
(Promega, Southampton, UK). The construct was checked by
digestion and sequencing.
Transfection
MCF-7 and MDA-MB-231 cells were transfected with the wild-
type class III b-tubulin (pALTER-TUBB3) or with the class III
b-tubulin siGenome Smartpool (siRNA-tubb3, ref. M-020099-03,
Dharmacon, Cramlington, UK) using the Amaxa nucleofection
technology (Amaxa GmbH, Koeln, Germany). The nucleofaction
protocol for plasmid transfection was optimised using a GFP-
construct with efficacies of 47 and 70% being achieved after
24h transfection in MCF-7 and MDA-MB-231 cells, respectively.
siRNA nucleofection was carried out using a pre-optimised
protocol (Mhaidat et al, 2008). Briefly, the cells were trypsinised
and washed with PBS. The required number of cells (2 10
6 cells
per nucleofection) were harvested, resuspended in nucleofactor
solution (100ml per nucleofection) and mixed with 2mg plasmid
or 4ml of siRNA (20mM). Cells were then electroporated in the
Amaxa nucleofector and transferred to fresh pre-warmed medium.
The cells were incubated for 1h at 371C before being seeded
in 96-well plates for proliferation assay or in T-25 flasks for protein
or RNA extraction. Transfection with the empty pALTER-Max
(mock transfection) and a non-targeting siRNA (siGENOME
Non-targeting siRNA, ref. D-001210-01, Dharmacon) had no
significant effect on the proliferation of either cell line (data not
shown).
Proliferation assay
The cells were seeded into 96-well culture plates at 4000 cells per
well, incubated at 371C for 24h and exposed to compounds for
96h at 371C. Cell proliferation was measured by adding 10ml
AlamarBlue reagent (BioSource International, Camarillo, CA,
USA). The viable cells are counted with a spectrofluorometric
microtiter-well plate reader Fluostar optima (BMG Labtech
GmbH, Offenburg, Germany) at 544nm (excitation) and 590nm
(emission). IC50 values were obtained from a graph of percent
proliferation vs inhibitor concentration and calculated using Prism
(Graphpad Software, La Jolla, CA, USA).
Immunoblotting
Proteins were extracted from the transfected cells by homogenisa-
tion in RIPA buffer (Sigma) in the presence of 10% protease
inhibitors and phosphatase inhibitors (ref. P2714, P5726 and
P2850; Sigma). The extracts were centrifuged (15min at 16000g
at 41C) and total protein concentrations were determined by
Bradford assay (Sigma). Protein samples (50mg) were denatured at
701C for 10min in loading buffer, separated by electrophoresis
using 4–12% Bis-Tris Nupage gels (Invitrogen, Paisley, UK) and
blotted onto a PVDF membrane (GE Healthcare, Bucks, UK).
Successful transfer and even protein loading was confirmed by
staining with Ponceau S Red (ref. 09189; Sigma). Only membranes
with even protein loading were further processed (data not
shown). The membrane was blocked with blocking buffer (4%
milk in PBS-Tween 1%) for 2h and incubated overnight at 41C
with the anti-human class III b-tubulin antibody (ref. MAB1637;
Millipore, Watford, UK) at 1:1000 or anti-human class I–V
b-tubulin antibody (ref. T4026; Sigma) at 1:200. The anti-human
a-tubulin was used as loading control at 1:1000 (ref. Ab6161;
Abcam, Cambridge, UK). An alkaline phosphatase-conjugated anti-
mouse (ref. 7056; Cell Signaling, Beverly, MA, USA) was used as
secondary antibody and the immunoblot was developed with a
chemifluorescent substrate (ECF substrate, ref. RPN5785; GE
Healthcare) and visualised using a Storm imaging system (GE
Healthcare). The data shown are representative of one of three such
experiments.
Real time RT–PCR
Cells were lysed with 350ml of RNeasy lysis buffer (Qiagen,
Ulm, Germany) plus 1% b-mercaptoethanol (Promega) and
homogenised with the QIAshredder columns (Qiagen). The RNA
was isolated from the homogenate using the RNeasy kit (Qiagen).
A5 mg aliquot of each RNA sample was reverse transcribed
using the First-Strand cDNA Synthesis kit (GE Healthcare).
Reverse-transcription–PCRs were carried out in a Rotor Gene
2000 Real-time Cycler (Corbett Research, Cambridge, UK) with
2ml cDNA in a final volume of 25ml using Taqman Universal
PCR Master Mix (Applied Biosystems, Foster City, CA, USA).
Primers and hydrolysis probes for class III b-tubulin (ref.
Hs00964965_m1) and for the internal housekeeping gene, RPLO,
(ref. 4310879E) were synthesised by Applied Biosystems. The
relative Ct values were calculated using the Rotor Gene 6 software
(Corbett Research, Cambridge, UK) and the comparative Cts were
given as:
amplificationefficiencyof targetgene-ðtargetCt of control targetCt of sampleÞ
amplificationefficiencyof referencegene-ðreferenceCt of control referenceCt of sampleÞ
Immunohistochemistry
MCF-7 and MDA-MB-231 cells grown on poly-L-lysine-coated
coverslips were exposed to compounds for 24h. The cells were
fixed in methanol at  201C for 10min, and then in ice-cold
acetone for 30s. Coverslips were rinsed and then rehydrated with
PBS. To visualise the microtubules, cells were incubated for 1h
with an a-tubulin-specific FITC-conjugated antibody (ref. F2168,
clone DM1A; Sigma) in PBS containing 1% BSA. Cells were washed
twice with PBS and counterstained with Hoechst 33342 at
1mgml
 1 (Sigma) to stain the nuclei. The coverslips were
mounted on slides using DePex mounting medium, observed
using a Zeiss inverted microscope ( 200) and analysed with the
Axiovision imaging system.
Statistics
In vitro experiments were carried out in triplicate and data
presented are representative of three or more independent
experiments. All errors shown are the mean±s.d. The Student’s
t-test was used to assess significance.
RESULTS
Class III b-tubulin mRNA expression and protein
expression
MCF-7 and MDA-MB-231 cells were transfected with mock vector,
non-targeting siRNA (MCF-7-control and MDA-MB-231-control),
pALTER-TUBB3 (MCF-7-TUBB3 and MDA-MB-231-TUBB3) or
siRNA-tubb3 (MCF-7-situbb3 and MDA-MB-231-situbb3). Gene
expression levels of class III b-tubulin were examined by RT–PCR.
The mRNA level of class III b-tubulin was 2±0.76-fold increased
in MCF-7-TUBB3 cells 24h after transfection (Po0.05) and
2.4±0.68-fold increased 5 days after transfection (Po0.01),
compared with MCF-7-mock-transfected cells (Figure 2A). The
mRNA level of class III b-tubulin was 4.4±2.6-fold increased
in MDA-MB-231-TUBB3 cells 24h after transfection (Po0.05)
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sand was 2.1±0.74-fold higher than the control level 5 days
after transfection (Po0.05, Figure 2B) relative to MDA-MB-231
mock-transfected cells. Transfection with siRNA-tubb3 blocked
the class III b-tubulin mRNA expression in both cell lines (Figure
2A and B). Class III b-tubulin mRNA levels were reduced by
50±16% in MCF-7-situbb3 cells 24h after transfection (Po0.05)
and by 46±16% 5 days after transfection (Po0.05). Class III
b-tubulin mRNA levels were also reduced by 36±15% in MDA-
MB-231-situbb3 cells 24h after transfection (Po0.01), but were
not significantly different from control cells 5 days after trans-
fection (90±47%).
To ensure changes in mRNA level correlated with protein
expression, MCF-7 and MDA-MB-231 cells were transfected with
either pALTER-TUBB3 or siRNA-tubb3 and the proteins were
extracted 24h and 5 days after transfection. Equal protein amounts
were analysed by SDS–PAGE and immunoblotting with the human
anti-class III b-tubulin or the human anti-class I–V b-tubulin.
Staining with Ponceau S and immunoblotting with an anti-
a-tubulin was used to ensure even protein loading and transfer.
Class III b-tubulin protein expression was higher in both cell lines
transfected with the pALTER-TUBB3 vector (Figure 2B and C, lane
2) and was lower in cells transfected with the class III b-tubulin
siRNA (Figure 2B and C, lane 3) compared with the control cells
(Figure 2B and C, lane 1). These changes in protein expression
were still observed 5 days after transfections (Figure 2B and C,
lanes 4, 5 and 6), except for MDA-MB-231 transfected with
MCF-7 cells MDA-MB-231 cells
3
2
1
0
5.0
7.5
2.5
0.0
C
l
a
s
s
 
I
I
I
 


-
t
u
b
u
l
i
n
 
m
R
N
A
-
l
e
v
e
l
 
r
e
l
a
t
i
v
e
 
t
o
 
c
o
n
t
r
o
l
*
**
* *
**
*
*
pALTER-TUBB3 24 h
siRNA-tubb3 24 h
pALTER-TUBB3 5 days
siRNA-tubb3 5 days
Control
pALTER-TUBB3 24 h
siRNA-tubb3 24 h
pALTER-TUBB3 5 days
siRNA-tubb3 5 days
Control
C
l
a
s
s
 
I
I
I
 

-
t
u
b
u
l
i
n
 
m
R
N
A
-
l
e
v
e
l
 
r
e
l
a
t
i
v
e
 
t
o
 
c
o
n
t
r
o
l
123
100% 153%
24 h
45%
4 56
100% 135%
5 days
63%
100% 157%
24 h
38% 100% 128%
5 days
95%
1234 5 6
Class III -tubulin
Total -tubulin
-Tubulin
Class III -tubulin
Total -tubulin
-Tubulin
Figure 2 Class III b-tubulin mRNA and protein expression. (A) MCF-7 and MDA-MB-231 cells were transfected with the mock vector or the non-
targeting siRNA (control), pALTER-TUBB3 or siRNA-tubb3 and the expression of class III b-tubulin mRNA was quantified by RT–PCR. Three or four
independent experiments (n¼3–4) were carried out in duplicate and the results presented are the average of the Ct values relative to the control Ct
values, bars: mean±s.d., *Po0.05 and **Po0.01. The expression of class III b-tubulin protein, total b-tubulin and total a-tubulin was analysed in (B) MCF-7
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the siRNA did not affect the amount of total b-tubulin expressed
in cells (Figure 2B and C). No change was observed for cells
transfected with the non-targeting siRNA (data not shown).
Proliferation assays
MCF-7 and MDA-MB-231 transfected cells were seeded at 4000
cells per well, incubated for 4 days and the percentage of
proliferation was monitored by using the Alamar blue reagent.
Class III b-tubulin overexpression or silencing did not significantly
affect the viability of the cells (the proliferation of MCF-7-TUBB3,
MCF-7-situbb3, MDA-MB-231-TUBB3 and MDA-MB-231-situbb3
cells was 105, 101, 97 and 98% respectively, the proliferation rate
of control cells, ns). The cytotoxicity efficacy of STX140, STX243,
2-MeOE2, ENMD1198 and colchicine was not significantly affected
by overexpression or silencing of class III b-tubulin (Figures 3
and 4, graphs A, B, D, E and G), and the IC50 values of these
compounds were not significantly different from IC50 values
calculated in control cells (Table 1a and b). Although MDA-MB-
231 cells underexpressing the class III b-tubulin were more
sensitive to colchicine than the mock-transfected cells when
exposed to high concentrations (0.1–10mM), the IC50 values in
both type of cells were not significantly different (IC50¼37nM in
MDA-MB-231-mock and IC50¼29nM in MDA-MB-231-situbb3,
Table 1b).
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Figure 3 STX140, STX243, 2-MeOE2, paclitaxel, ENMD1198, vinorelbine and colchicine chemosensitivity in MCF-7 cells. MCF-7 cells were transfected
with the mock vector or the non-targeting siRNA (control), (A) pALTER-TUBB3 or siRNA-tubb3 and exposed to STX140, (B) STX243, (C) paclitaxel, (D)
2-MeOE2, (E) ENMD1198, (F) vinorelbine or (G) colchicine for 4 days. The percent proliferation was determined by AlamarBlue assay and results
presented are the average of three or four independent experiments (n¼3–4) done in triplicate, *Po0.05 and **Po0.01.
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in both cell lines (Figures 3C and 4C). MCF-7 and MDA-MB-231
cells overexpressing class III b-tubulin were the less sensitive to
paclitaxel, with IC50 values of 0.1nM and 4pM, respectively (Table
1a and b). These IC50 values were significantly higher (Po0.01)
than those obtained in untreated MCF-7 and MDA-MB-231 cells
(7.2 and 2pM, respectively). In contrast, MCF-7 and MDA-MB-231
cells underexpressing class III b-tubulin were found to be the most
sensitive to paclitaxel. Paclitaxel’s IC50 value was significantly
reduced in MCF-7-situbb3 cells (IC50¼4.8pM, Po0.05) compared
to the IC50 value in control cells. Despite reducing the paclitaxel
concentration to 0.1pM,n oI C 50 values could be obtained for
the MDA-MB-231 cells underexpressing class III b-tubulin as
the inhibition of growth was greater than 50% (47%, Figure 4C).
At higher concentrations (1 and 10pM), the class III b-tubulin
silencing rendered MDA-MB-231 cells significantly more sensitive
to paclitaxel than the control cells (Po0.05 and Po0.01, respec-
tively, Figure 4C).
The modification of the b-tubulin expression profile also altered
the efficacy of vinorelbine (Figures 3F and 4F). When MCF-7 and
MDA-MB-231 cells were transfected with pALTER-TUBB3, the
IC50 values for vinorelbine were higher than the IC50 values in the
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Figure 4 STX140, STX243, 2-MeOE2, paclitaxel, ENMD1198, vinorelbine and colchicine chemosensitivity in MDA-MB-231 cells. MDA-MB-231 cells
were transfected with the mock vector or the non-targeting siRNA (control), (A) pALTER-TUBB3 or siRNA-tubb3 and treated with STX140, (B) STX243,
(C) paclitaxel, (D) 2-MeOE2, (E) ENMD1198, (F) vinorelbine or (G) colchicine for 4 days. The percent proliferation was determined by AlamarBlue assay
and results presented are the average of three or four independent experiments (n¼3–4) done in triplicate, *Po0.05, **Po0.01 and ***Po0.001.
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0.25mM in MDA-MB-231-TUBB3 cells, whereas they were equal to
0.06mM in MCF-7-control and 0.12mM in MDA-MB-231-control
cells, Table 1a and b). The MCF-7 cells transfected with class III
b-tubulin silencing RNA were the most sensitive to vinorelbine
and their IC50 value was equal to 0.01mM. Underexpression of
class III b-tubulin did not affect the sensitivity of MDA-MB-231
cells to vinorelbine and the IC50 value in these cells remained the
same as in control cells (IC50¼0.12mM in MDA-MB-231-situbb3).
Microtubule structure
To investigate whether class III b-tubulin resistance is reflected at
the cytoskeleton structure level, cells overexpressing class III
b-tubulin were exposed to STX140, paclitaxel and colchicine for
48h at concentrations close to IC50 values obtained in control
cells. Nuclear and cytoskeletal morphology was then examined
by immuno-fluorescence microscopy. The untreated cells showed
typical nuclear and cytoskeleton structures, with long and dense
microtubules extending throughout the cytoplasm. No significant
difference was observed in the morphology of both untreated cell
lines overexpressing class III b-tubulin compared with control cells
(Figure 5). STX140 and colchicine caused microtubule disruption
with bundles of microtubules being observed and overexpression
of class III b-tubulin did not affect the morphological changes in
either cell line in response to these compounds. In the non-
transfected MCF-7 control cells paclitaxel caused the virtual
destruction of the normal microtubule structure with only very
small and dense bundles of microtubules being visible. Further-
more, many abnormal nuclei were observed in comparison to
untreated cells and those exposed to either STX140 or colchicine.
Morphological changes were seen in the MCF-7 class III b-tubulin
overexpressing cells in response to paclitaxel, with shortened but
unusually highly defined microtubules and many abnormal nuclei
present. The unusual microtubule structures seen in the MCF-7
class III b-tubulin overexpressing cells in response to paclitaxel
were not observed in their MDA-231 counterparts which far more
closely resemble the non-transfected MDA-231 control cells after
paclitaxel exposure. Although tubulin III transfection renders
both cells lines significantly more resistant to paclitaxel, effects on
microtubule structure were seen in this study as the concentration
of paclitaxel used was still cytotoxic. Further studies are planned to
understand the unusual structures observed in the MCF-7 class III
b-tubulin overexpressing cells.
DISCUSSION
Tubulin-binding agents constitute an important class of com-
pound in chemotherapy, but their clinical success has been
compromised by the emergence of drug resistance, which is
derived from several mechanisms that can be de novo or acquired.
Tubulin-binding agents target the microtubule network and
two different resistance mechanisms have been associated to the
taxane-resistant phenotype in cancer patients: the overexpression
of ATP-binding cassette family of proteins such as P-glycoprotein
and alterations in tubulin-isoform expression. Previous studies
showed that some compounds such as STX140, are able to inhibit
the proliferation of resistant MCF-7dox cells (P-gly þve) by
arresting them in the G2/M phase (Suzuki et al, 2003) and to block
the growth of MCF-7dox tumours (Newman et al, 2008). This
study is the first to report the effects of changes in the tubulin-
isoform expression profile on the efficacy of new tubulin-binding
agents, including Panzem (2-MeOE2), ENMD1198 (currently in
phase I clinical trials) and STX140 in MCF-7 and MDA-MB-231
cells.
Identifying the role of class III b-tubulin in drug resistance is
difficult because of the complexity of tubulin auto-regulation.
Expression of b-tubulin isotypes is tightly regulated through
co-translational degradation of b-tubulin mRNAs in response to
an increase in the level of soluble tubulin (Yen et al, 1988;
Theodorakis and Cleveland, 1992). This may explain why over-
expression of class III b-tubulin failed to confer resistance to
paclitaxel, estramustine and vinblastine, among other drugs tested
in prostate cells (Ranganathan et al, 2001). In addition, too high
expression of class III b-tubulin in cells can be toxic, further
complicating this methodology (Hari et al, 2003). To negate this
problem Hari et al (2003) inducibly overexpressed class III
b-tubulin in CHO cells, this decreased the paclitaxel suppression
of microtubule dynamics and caused a limited resistance to pacli-
taxel (Kamath et al, 2005). Recently, cervical carcinoma HeLa cells
were stably transfected with class III b-tubulin (Joe et al, 2008) and
Table 1 Average IC50 values of STX140, STX243, STX66, paclitaxel, ENMD1198, vinorelbine and colchicine in (a) MCF-7 and (b) MDA-MB-231 cells
MCF-7 cells Avg IC50 values (lM) Mock pALTER-TUBB3 siRNA-tubb3
(a)
STX140 0.98 1.06 0.92
STX243 0.69 0.81 0.73
2-MeOE2 0.99 0.97 0.98
Paclitaxel 7.2 10
 6 1 10
 4** 4.8 10
 6*
Vinorelbine 0.06 1** 0.01*
ENMD1198 0.57 0.61 0.45
Colchicine 0.024 0.029 0.029
MDA-MB-231 cells Avg IC50 values (lM) Mock pALTER-TUBB3 siRNA-tubb3
(b)
STX140 0.05 0.08 0.07
STX243 0.08 0.10 0.09
2-MeOE2 0.99 0.98 0.99
Paclitaxel 2 10
 6 4 10
 6*** o1 10
 7**
Vinorelbine 0.12 0.25** 0.12
ENMD1198 0.08 0.09 0.09
Colchicine 0.037 0.042 0.029
Cells were transfected with pALTER-TUBB3 or siRNA-tubb3. They were then exposed to STX140, STX243, paclitaxel, STX66, ENMD1198, vinorelbine or colchicine for 4 days
and the IC50 values were obtained from a graph of percent proliferation vs inhibitor concentration and calculated using Prism (Graphpad Software). ***Po0.001, **Po0.01 and
*Po0.05.
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swere used to test taccalonolides, which were shown not to be
susceptible to class III b-tubulin resistance (Risinger et al, 2008).
In this study, class III b-tubulin protein levels was only 1.5-fold
increased in cells transfected with pALTER-TUBB3. This may have
protected the cells against the toxicity of high expression and
enabled them to grow with a similar proliferation rate than control
cells. However, the overexpression of class III b-tubulin was
significant and this degree of overexpression was sufficient to
confer a resistance to paclitaxel. These data are supported by the
relatively small increase (five-fold) seen in patients with docetaxel-
refractory breast cancer (Hasegawa et al, 2003).
This study demonstrates that a variation in the b-tubulin
expression pattern in two breast cancer cell lines does not affect
the efficacies of STX140, STX243, 2-MeOE2, ENMD1198 and
colchicine, whereas the efficacy of vinorelbine and paclitaxel are
altered by both class III b-tubulin overexpression and silencing.
These results correlate with previous studies using siRNA
approaches which showed that class III b-tubulin induces
resistance to paclitaxel, vincristine and DNA-damaging agents in
non-small cell lung carcinoma (Kavallaris et al, 1999; Gan et al,
2007).
The key difference between class I and class III b-tubulin is an
amino-acid substitution leading to a different three dimensional
conformation. Class III b-tubulin, which presents only 92% simi-
larity with the other b-tubulin isoforms, bears an Arg
277 instead
of the Ser
277 present in class I b-tubulin. Ser
277 and Arg
278 are
essential for the stable binding of paclitaxel to its binding site in
class I b-tubulin (Lowe et al, 2001). In contrast, the structure of the
loop of the class III b-tubulin is altered by the substitution of Ser
277
with Arg and thus, prevents a stable paclitaxel binding (Ferlini
et al, 2005). It has been shown that Class III b-tubulin also
generates more dynamic microtubules and counteracts pro-
assembling activity of taxanes at the plus ends of microtubules
(Kamath et al, 2005), thereby making microtubules more resistant
to the stabilisation of microtubule dynamics operated by taxanes
(Hari et al, 2003; Kamath et al, 2005; Gan et al, 2007). In contrast,
STX140, STX243, 2-MeOE2, ENMD1198 and colchicine are
structurally different to paclitaxel; they bind to the colchicine site
and they have a conformation, which may allow the formation of
a stable complex with class III b-tubulin. Moreover, these
agents depolymerise microtubules, whereas paclitaxel stabilises
them. This may be a great advantage when class III b-tubulin
is overexpressed and the microtubule dynamic is amplified.
However, vinorelbine, which is also a microtubule-destabilising
agent but binds to the Vinca alkaloid binding site, has its efficacy
reduced by the overexpression of class III b-tubulin in vitro
in breast carcinoma cells (as shown in this study) and in small
lung cancer cells (Gan et al, 2007) and in vivo (Seve et al, 2005).
Therefore, class III b-tubulin resistance might be binding-site
related and agents binding to the colchicine-binding site might
avoid this resistance. This theory is supported by a recent study,
wherein the authors showed that HeLa cells overexpressing class
MCF-7 control
MCF-7 TUBB3
MDA-MB-231 control
20M
MDA-MB-231 TUBB3
Untreated STX140 Paclitaxel Colchicine
Figure 5 Fluorescent images of cells overexpressing class III b-tubulin after drug exposure. MCF-7-control, MCF-7-TUBB3, MDA-MB-231-control and
MDA-MB-231-TUBB3 cells were treated for 48h with STX140, paclitaxel or colchicine at concentrations close to IC50 values obtained in control cells and
stained with FITC-anti-tubulin (tubulin) and Hoechst 33342 (nucleus). Images were taken using a Zeiss inverted microscope at  200 magnification.
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and vinblastine. Furthermore, the efficacy of the taccalonolides,
which do not interact with microtubules despite having paclitaxel-
like effects in cells, is unaffected by class III b-tubulin expression
(Risinger et al, 2008).
In summary, this study shows that microtubule disrupting
agents binding to the colchicine-binding site circumvent class III
b-tubulin resistance, whereas agents binding to the taxol- or the
Vinca-binding sites have their efficacies altered by changes in class
III b-tubulin expression. Class III b-tubulin is associated with drug
resistance and poor prognosis in patients (Hasegawa et al, 2003;
Mozzetti et al, 2005; Seve et al, 2005; Urano et al, 2006; Tommasi
et al, 2007) and it is a predictive factor of event-free and overall
survival (Seve and Dumontet, 2008). Moreover, class III b-tubulin
is involved in the sensitivity of both taxanes and Vinca alkaloids,
but it also has a role in chemosensitivity of DNA-damaging agents
(Gan et al, 2007). This study therefore highlights the importance
of developing new agents binding to the colchicine-binding site,
such as STX140 and STX243 as an alternative to taxanes for
refractory cancer treatment.
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